Abstract:Gene therapies for genetic diseases have been sought for decades, and the relatively recent development of the CRISPR/Cas9 gene-editing system has encouraged a new wave of interest in the field. There have nonetheless been significant setbacks to gene therapy, including unintended biological consequences, ethical scandals, and death. The major focus of research has been on technological problems such as delivery, potential immune responses, and both on and off-target effects in an effort to avoid negative clinical outcomes. While the field has concentrated on how we can better achieve gene therapies and gene editing techniques, there has been less focus on when and why we should use such technology. Here we combine discussion of both the technical and ethical barriers to the widespread clinical application of gene therapy and gene editing, providing a resource for gene therapy experts and novices alike. We discuss ethical problems and solutions, using cystic fibrosis and beta-thalassemia as case studies where gene therapy might be suitable, and provide examples of situations where human germline gene editing may be ethically permissible. Using such examples, we propose criteria to guide researchers and clinicians in deciding whether or not to pursue gene therapy as a treatment. Finally, we summarize how current progress in the field adheres to principles of biomedical ethics and highlight how this approach might fall short of ethical rigour using examples in the bioethics literature. Ultimately by addressing both the technical and ethical aspects of gene therapy and editing, new frameworks can be developed for the fair application of these potentially life-saving treatments.

The immune system can sabotage gene therapies — can scientists rein it in?

Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy

Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?

Cas9 immunity creates challenges for CRISPR gene editing therapies

Stealthy stem cells to treat disease

Engineering immune-evasive allogeneic cellular immunotherapies

Gene Therapy Leaves a Vicious Cycle

Immunology of cell and gene therapy approaches for neurologic diseases

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

The immune boundaries for stem cell based therapies: problems and prospective solutions

Gene therapy comes of age

Gene knockout in cellular immunotherapy: Application and limitations

Genetic engineering of T cells for immunotherapy

Immune Responses to Viral Gene Therapy Vectors

The once and future gene therapy

Rare immune diseases paving the road for genome editing-based precision medicine

Potential role for oral tolerance in gene therapy

Immunodeficiency: Gene therapy for primary immune deficiency

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Gene Therapy In Kidney Transplantation: Evidence Of Efficacy And Future Directions.